For the fiscal year ending December 2026, revenue reached 1.3323 trillion yen (12.8% increase), with midterm profit hitting 218.5 billion yen (24.3% increase), setting a new record. Segment performance was also strong, driven by the healthcare-related and Nutraceuticals segments.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4578","jir_company_name":"Otsuka Holdings Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-07-31","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/07\/4578-20260731-01.pdf","jir_short_summary":"For the fiscal year ending December 2026, revenue reached 1.3323 trillion yen (12.8% increase), with midterm profit hitting 218.5 billion yen (24.3% increase), setting a new record. Segment performance was also strong, driven by the healthcare-related and Nutraceuticals segments.","jir_summary":"### Performance Overview\nOtsuka Holdings recorded a midterm revenue of 1.3323 trillion yen (up 12.8% YoY) and a midterm profit of 218.5 billion yen (up 24.3% YoY) for the fiscal period ending December 2026, reaching new highs. The strong performance of the healthcare and Nutraceuticals segments substantially contributed to the growth in revenue and profit, particularly driven by increased sales of antipsychotics and anticancer agents. R&D expenses also increased, supporting progress in new drug candidates and expansion through acquisitions. Both assets and liabilities increased, and treasury stock acquisitions and dividend payouts were also implemented.\n\n### Outlook and Impact on Shareholders\nFull-year earnings forecast for 2026 has been revised upward, with expected revenue of 2.725 trillion yen (an increase of 205 billion yen from previous forecast) and net profit of 360 billion yen (an increase of 91 billion yen). Continued growth in sales of antipsychotics and anticancer drugs, along with ongoing R&D efforts, underpin steady performance. Shareholder returns via treasury stock acquisitions and increased dividends are expected to continue, making the company attractive to investors. While forex and geopolitical risks should be considered, the growth strategy is viewed as sound.","jir_financial_highlights":"Revenue: 1,332,390 million yen (YoY 12.8% increase)\nMidterm Profit: 218,542 million yen (YoY 24.3% increase)\nNet Income attributable to owners of the parent: 215,612 million yen (YoY 24.3% increase)","jir_category":"","jir_hashtags":"#OtsukaHoldings, #IRFinancialResults, #JapanStocks","jir_key_figures":"Revenue: 1,332,390 million yen (YoY 12.8% increase)\nMidterm Profit: 218,542 million yen (YoY 24.3% increase)\nNet income attributable to owners of the parent: 215,612 million yen (YoY 24.3% increase)","jir_meta_title":"\u3010Otsuka Holdings\u30112026 Midterm Financial Results | Record High Profit with 12.8% Revenue Growth","jir_meta_description":"Detailed analysis of Otsuka Holdings' 2026 midterm financial results. Revenue increased by 12.8% to 1.3323 trillion yen, with substantial profit growth. Future outlook also explained.","jir_og_title":"\u3010Otsuka HD\u30112026 Midterm Financial Results | 12.8% Revenue Increase, Record High Profit","jir_og_description":"Overview of Otsuka Holdings' 2026 midterm financial results and future prospects. Highlights of revenue growth and profit expansion.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":6875,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-91409","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n